Ceralasertib

Ceralasertib

Chemical structure of Ceralasertib

Ceralasertib is a small molecule inhibitor of the enzyme ataxia telangiectasia and Rad3-related protein (ATR), which is involved in the DNA damage response pathway. It is being investigated for its potential use in the treatment of various types of cancer.

Mechanism of Action

Ceralasertib functions by inhibiting ATR, a key protein kinase that plays a critical role in the cellular response to DNA damage. ATR is activated in response to replication stress and DNA damage, leading to cell cycle arrest and DNA repair. By inhibiting ATR, ceralasertib prevents the repair of damaged DNA in cancer cells, thereby enhancing the cytotoxic effects of DNA-damaging agents and potentially leading to increased cancer cell death.

Clinical Development

Ceralasertib is currently undergoing clinical trials to evaluate its efficacy and safety in combination with other anticancer therapies. It is being tested in various cancer types, including ovarian cancer, lung cancer, and breast cancer. The combination of ceralasertib with chemotherapy or immunotherapy is of particular interest, as it may enhance the therapeutic effects of these treatments.

Potential Benefits

The inhibition of ATR by ceralasertib offers a promising strategy for targeting tumors with specific genetic backgrounds, such as those with deficiencies in the BRCA1 or BRCA2 genes. These tumors are often more reliant on ATR for survival, making them particularly susceptible to ATR inhibition.

Side Effects

As with many anticancer agents, ceralasertib may cause side effects. Commonly reported adverse effects include fatigue, nausea, and hematological toxicities such as anemia and thrombocytopenia. The safety profile of ceralasertib is being closely monitored in ongoing clinical trials.

Related Pages

• ATR (protein)
• DNA damage response
• Cancer treatment
• Chemotherapy
• Immunotherapy